Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis

BACKGROUND: Eribulin is a microtubule inhibitor, which is approved for the treatment of breast cancer. Peripheral neuropathy has been reported in the studies of eribulin, but the incidence and relative risk (RR) of eribulin-associated peripheral neuropathy varied greatly in cancer patients. The purp...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ling, Hong, Yun, Ye, Xianghua, Shi, Peng, Zhang, Junyan, Wang, Yina, Zhao, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762380/
https://www.ncbi.nlm.nih.gov/pubmed/29340112
http://dx.doi.org/10.18632/oncotarget.21057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762380/
https://www.ncbi.nlm.nih.gov/pubmed/29340112
http://dx.doi.org/10.18632/oncotarget.21057

Ejemplares similares